Encompass Health Co. (NYSE:EHC) Director Greg D. Carmichael Acquires 2,000 Shares

Encompass Health Co. (NYSE:EHC) Director Greg D. Carmichael bought 2,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was bought at an average cost of $83.73 per share, with a total value of $167,460.00. Following the completion of the acquisition, the director now owns 17,050 shares in the company, valued at approximately $1,427,596.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Encompass Health Stock Up 1.7 %

NYSE EHC opened at $85.93 on Wednesday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. Encompass Health Co. has a 52 week low of $57.55 and a 52 week high of $86.60. The stock has a market capitalization of $8.65 billion, a P/E ratio of 23.22, a price-to-earnings-growth ratio of 1.30 and a beta of 0.92. The stock has a fifty day moving average of $79.33 and a 200-day moving average of $71.79.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the prior year, the company posted $0.88 EPS. The company’s revenue was up 13.4% compared to the same quarter last year. On average, equities research analysts forecast that Encompass Health Co. will post 4.1 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Monday, July 1st will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Friday, June 28th. Encompass Health’s payout ratio is 16.22%.

Analysts Set New Price Targets

A number of brokerages have issued reports on EHC. Barclays lifted their price objective on Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Mizuho boosted their price target on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a report on Wednesday, February 7th. Raymond James reissued a “strong-buy” rating and issued a $95.00 target price (up from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Finally, Truist Financial raised their price target on Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a report on Friday, February 9th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $90.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. QRG Capital Management Inc. increased its holdings in Encompass Health by 23.4% in the first quarter. QRG Capital Management Inc. now owns 7,738 shares of the company’s stock valued at $639,000 after purchasing an additional 1,467 shares during the last quarter. Inspire Investing LLC increased its stake in shares of Encompass Health by 75.4% in the 1st quarter. Inspire Investing LLC now owns 34,470 shares of the company’s stock valued at $2,847,000 after acquiring an additional 14,818 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Encompass Health in the 1st quarter valued at approximately $816,000. Tectonic Advisors LLC boosted its stake in Encompass Health by 12.0% during the 1st quarter. Tectonic Advisors LLC now owns 6,262 shares of the company’s stock worth $517,000 after acquiring an additional 672 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in Encompass Health by 5.6% during the first quarter. Oppenheimer & Co. Inc. now owns 118,201 shares of the company’s stock valued at $9,761,000 after purchasing an additional 6,280 shares during the period. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.